Amble review
Amble is a managed-services telehealth platform (by its own terms, not itself a medical facility or pharmacy) selling compounded semaglutide and tirzepatide at IDENTICAL prices on a commitment-length pricing table: $179/mo with no commitment.
- Semaglutide
- $179/mo (all doses, compounded)
- Tirzepatide
- $179/mo (all doses, compounded)
- Coverage
- All 50 states
- Brand-name
- Compounded only
Semaglutide · modeled / year
$2,148
Tirzepatide · modeled / year
$2,148
Pricing verified August 2026
The Index scorecard
Amble scored on our six Cost-Efficiency Index factors. See the methodology.
Where the value is
- No difference in price between semaglutide and tirzepatide — genuinely one pricing table for both
- True no-commitment option exists ($179/mo, pay as you go) alongside the prepay tiers
- All 50 states, with only 5 requiring a live video visit instead of async intake
- HSA/FSA cards accepted on 3-month-or-longer plans
The tradeoffs
- The advertised low-end price ($135-$160/mo) is not a monthly bill — it's a one-time lump-sum prepay for the whole 3/6/12-month term, stated explicitly on the page
- No named medical director, prescriber, or compounding pharmacy anywhere on the site
- No LegitScript certification found on the site
- Amble's own terms state it 'does not offer medical advice, fill prescriptions, or function as a licensed healthcare facility or pharmacy' — it is an intermediary layer, not the treating entity
The bottom line
Best for: Cost-first shoppers who want a single flat rate across semaglutide and tirzepatide, if a 12-month prepay is acceptable. Amble is a managed-services telehealth platform (by its own terms, not itself a medical facility or pharmacy) selling compounded semaglutide and tirzepatide at IDENTICAL prices on a commitment-length pricing table: $179/mo with no commitment.
Ranked #56 of 539 providers on the Cost-Efficiency Index — see our #1 pick, CoreAge Rx, for comparison.
Compare with other providers
All 538 other providers we've modeled, in Cost-Efficiency Index order. See the ranked alternatives to Amble.
- #50NiceRx— NiceRx is a compounded GLP-1 telehealth platform charging $199/mo for semaglutide and $299/mo for tirzepatide on an ongoing month-to-month basis (first month discounted to $99 and $199 respectively).76/100
- #51Vytora Health— Vytora Health (Wasef Health, PC) is a 50-state-plus-DC telehealth platform selling flat-rate compounded semaglutide and tirzepatide alongside retail-priced brand-name Mounjaro and Zepbound ($1,399/mo each).76/100
- #52Rylo Health— Rylo Health is a compounded GLP-1/NAD+/peptide telehealth platform operating in all 50 states through Lone Star Virtual Health PLLC and dispensing via VialsRX in Houston, TX.75/100
- #53Synergy Rx— Brand Wegovy, Ozempic or Mounjaro when clinically appropriate, with unlimited round-the-clock clinical contact — at prices its own site never shows.72/100
- #54Peter MD— One account across six verticals — TRT, ED, weight loss, GLP-1, men's hair loss and NAD+ — from a physician-prescribed telehealth brand running since 2021, at a renewal price ($249/mo tirzepatide) well above its own $149 first-month headline.72/100
- #55EdgeRx— The best clinical documentation of any newly added row — a named Chief Medical Advisor and a named 503A pharmacy — but it's a men's-only platform, not a fit for every reader.74/100
The 24 programs nearest this one
- #57 Aspen74
- #58 DoctorAdam74
- #59 Jyra Health74
- #60 Nalena74
- #61 NextMeds74
- #62 Science & Co74
- #63 Gala Health71
- #64 Direct Meds71
- #65 He & She MD71
- #66 SkinnyRx71
- #67 Amazon One Medical73
- #68 MyFastRx73
- #69 Navio MD73
- #70 Ozari Health73
- #71 Trillium Meds73
- #72 Clume Health73
- #73 BiltRx72
- #74 Candor Rx72
- #75 Get Thin MD72
- #76 Heally72
- #77 Recovery Delivered72
- #78 Nova72
- #79 Bodybuilding Health+69
- #80 Apex MD71
Pricing, states and verification reflect Amble's public disclosures at last review; the Cost-Efficiency Index is our editorial judgment per the methodology. Prices change — confirm on Amble's site. Not medical advice; see our disclosure.